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Abstract
Nosocomial bloodstream infections (BSIs) are an important cause of morbidity and mortality. The current study analysed data from a
concurrent surveillance programme to examine the current epidemiological trends for nosocomial BSIs at 22 Japanese university hospitals
from 1 April 2008 to 31 March 2012. The number of blood culture sets taken, the rate of multiple blood culture sets and the rates of
antibiotic-resistant isolates among six major nosocomial BSI pathogens (Staphylococcus aureus, Enterococcus spp., Escherichia coli, Klebsiella
spp., Pseudomonas aeruginosa, and Candida spp.) not including coagulase-negative staphylococci, were evaluated. The clinical characteristics of
nosocomial BSIs caused by these pathogens were also collected for 2941 patients. The number of blood culture sets taken per bed
increased during the 4-year study period (from 4.07 in 2008 to 5.37 in 2011), and the rates of multiple blood culture sets also increased
(from 29.9% in 2008 to 50.0% in 2011). Methicillin resistance was detected in 50.2% of S. aureus isolates. The prevalence rates of extended-
spectrum beta-lactamase-producing E. coli and Klebsiella spp. isolates increased annually during the study period, and the average prevalence
rates were 12.3% and 5.8%, respectively. The overall crude mortality of nosocomial BSIs due to the six pathogens evaluated was 24.5%
(43.2% in ICU settings and 20.5% in non-ICU settings). Thus, our multicentre study evaluated the current epidemiological trends for
nosocomial BSIs, and we found that further efforts are needed to increase the use of multiple blood culture sets and improve the prognosis
of nosocomial BSIs in Japanese university hospitals.
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Introduction
Nosocomial bloodstream infections (BSIs) are a major cause of
morbidity and mortality worldwide [1,2]. The incidence of
nosocomial BSIs is increasing, as is the prevalence of antibiotic
resistance among the pathogens that cause these infections [3–6].
The primary objective of national hospital infection programmes
is to promote surveillance by providing a uniform approach to
surveillance among participating hospitals and to offer country-
speciﬁc data on nosocomial infections. Surveillance of nosocomial
BSIs is the cornerstone of prevention and control for each
participating hospital [7,8], and nationally aggregated data make
international comparisons possible [9,10]. However, few data on
nosocomial infections, including the clinical characteristics and the
causative agents of these infections, have been collected through
surveillance programmes in Japan.
The Infection Prevention and Control Conference for
National and Public University Hospitals was organized in 2000
to improve the levels of infection control in Japan by
developing new guidelines for infection control that are
suitable for the Japanese medical system and by performing
surveillance for nosocomial infections. At this conference,
some sectional meetings, including surveillance groups, were
organized. In the present article, we report the ﬁrst results
from the analysis of the combined data from the 21 hospitals
that participated in the surveillance programme for nosocomial
BSIs during 2008–2012. This study was conducted to assess
the epidemiological features of nosocomial BSIs in Japan.
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Materials and Methods
Study design
This study was performed in 22 of the Japanese university
hospitals that participated in the Infection Prevention and
Control Conference for National and Public University
Hospitals; a total of 42 national university hospitals partic-
ipated in this group in 2008. The surveillance was prospective
and hospital wide, covering all patients admitted to the
hospitals from April 2008 to March 2012. The data were tallied
according to the ﬁscal year, which begins in April and ends in
March. There were two types of surveillance that could be
selected by each participating university: (i) surveillance using
the microbiological results of blood cultures and/or (ii)
surveillance of the clinical characteristics of nosocomial BSIs
caused by six pathogens (Staphylococcus aureus, Enterococcus
spp., E. coli, Klebsiella spp., Pseudomonas aeruginosa and Candida
spp.). These six pathogens represent the major cause of
bloodstream infections in Japan, according to the report on
Japanese nosocomial infections surveillance performed by the
Ministry of Health, Labour and Welfare of Japan (http://www.
nih-janis.jp/index.asp, September 2012). Coagulase-negative
staphylococci were omitted because the rate of solitary blood
culture sets was thought to be high in Japan, and therefore, the
actual incidence of BSIs was considered to be too difﬁcult to
calculate in this study. Clinical information and microbiological
data were recorded by local infection control practitioners on
a standardized case record form and entered into a common
database that was set up for the study. For this study, any
positive blood culture obtained >48 h after admission was
considered to be indicative of nosocomial infection, provided
that the same organism had not been previously isolated from
the patient.
Surveillance of the microbiological results of blood cultures. For this
analysis, the number of blood culture sets taken, the rates of
multiple blood culture sets performed on the same day, the
number of BSIs caused by the six major pathogens and the
number of BSIs caused by resistant isolates were counted.
Each blood sample collected by a separate venipuncture,
regardless of how the sample was apportioned, was deﬁned as
one set. The rate of multiple culture sets was calculated as
follows: (total number of blood culture setstotal number of
solitary blood culture sets)/total number of blood culture
sets 9 100 (%)).
Surveillance of the clinical characteristics of nosocomial BSIs due to
the six major pathogens. The routinely collected data included
the patient’s age, sex and location at the onset of the BSI (ICU
vs. non-ICU ward), clinical procedure performed at the onset
of the BSI, predisposing clinical conditions, the source of
secondary BSIs, and the outcome during hospitalization (i.e.
crude mortality). Predisposing clinical conditions that were
routinely recorded included neutropenia (deﬁned as an
absolute neutrophil count <500 cells/lL), peritoneal dialysis
or haemodialysis, and/or the presence of intravascular cathe-
ters.
Incidence
To calculate incidence rates, we collected admission data from
the participating hospitals. The incidence rates of nosocomial
BSIs caused by the six pathogens were calculated as the
number of BSIs per 1000 patient-days. To calculate the number
of blood culture sets taken, we determined the number of
beds in each participating hospital. According to the guidelines
for blood cultures, the optimal numbers of blood culture sets
should be 103–188 per 1000 patient-days [11]. However, the
average numbers of hospitalization days differ among coun-
tries; for example, the average number of hospitalization days
in the United States was reported to be 4.9 days, whereas this
number was 18.2 days in Japan (http://www.oecd.org/health/
healthpoliciesanddata/oecdhealthdata2012.htm). Thus, to com-
pare the number of blood culture sets in our study with this
previous report, the number of blood culture sets taken was
measured per bed.
Microbiological methods
Each participating hospital laboratory detected growth in
blood cultures, identiﬁed organisms, and performed suscepti-
bility testing. The identiﬁcation of blood isolates and suscep-
tibility testing were performed with the routine methods in
use at the afﬁliated laboratories. The data from all hospitals
were used for the analysis.
Results
Number of blood culture sets taken and the rate of multiple
blood culture sets
Seventeen hospitals participated in the surveillance of micro-
biology results (average, 766 beds; range, 562–1240). The
average number of blood culture sets taken per bed increased
from 4.07 per bed (range, 2.00–6.83) in 2008 to 5.36 per bed
(range, 2.44–7.34) in 2012. The number of blood culture sets
per 1000 patient-days also increased from 12.3 to 15.4, and the
average rate of multiple blood culture sets increased signiﬁ-
cantly from 29.9% (range, 6.3–77.2%) to 50.0% (range, 21.7–
77.7%) during this time (Fig. 1).
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Microbiological features and antimicrobial susceptibility
The BSI episodes per 1000 patient-days and the rates of
resistant isolates are shown in Table 1. BSIs due to E. coli,
Enterococcus spp. and Candida spp. increased annually during
the study period. The proportion of S. aureus isolates resistant
to methicillin was 50.2% on average, although this proportion
seemed to decline from 2009 to 2011 (Fig. 2). Among
Enterococcal isolates, penicillin resistance was observed in
31.4% of the Enterococcal isolates. Extended spectrum beta-
lactamase (ESBL)-producing E. coli and Klebsiella spp.
accounted for 12.3% and 5.8% of these isolates, respectively.
In addition, these percentages increased during the study
period. In total, 10.1%, 1.7% and 2.7% of P. aeruginosa isolates
were ceftazidime-resistant, metallo-beta-lactamase producing
and multidrug resistant, respectively.
Clinical characteristics of BSIs
The clinical characteristics of the 2941 patients with nosoco-
mial BSIs caused by the six major pathogens were submitted by
11 hospitals (average, 761 beds; range, 604–1240) (Table 2).
One hundred and thirty-three episodes of BSI (4.5%) were
identiﬁed in paediatric patients (<16 years of age). The mean
age of the patients was 61.3 years (range, 0–92 years) and
60.1% of the patients were male. Approximately 12% of
nosocomial BSI cases caused by the six major pathogens
occurred in the ICU. The most frequent underlying conditions
included solid tumours in 1166 patients (39.6%) and diabetes
mellitus in 435 patients (14.8%). Among the potential factors
predisposing patients to BSIs, intravascular devices were the
most frequent. In total, 309 patients (10.5%) required dialysis
at the onset of BSIs. Overall, 720 patients died during
hospitalization, resulting in a crude mortality rate of 24.5%.
The source of the nosocomial BSIs was evaluated for 2941
cases and Table 3 depicts the clinical characteristics and crude
mortality rates of patients with nosocomial BSIs according to
the type of organism isolated. Of note, the crude mortality
rates were different for the same pathogen when the source of
infection was different (Table 4). Regarding the speciﬁc micro-
organisms identiﬁed, the highest crude mortality rate was
observed for Candida spp., followed by Enterococcus spp. and
S. aureus. Regarding the source of the BSIs, the highest mortality
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FIG. 1. Number of blood culture sets taken
per bed (a) and the rates of multiple blood
culture sets (b) for 17 university hospitals in
Japan. *ESBL, extended spectrum beta lactam-
ase. **MBL, metallo-beta-lactamase. The aver-
age number of blood culture sets taken per bed
increased from 4.07 per bed in 2008 to 5.36 per
bed in 2012. The average rate of multiple blood
culture sets increased from 29.9% to 50.0%
during this time.
TABLE 1. Incidence rates of the six major pathogens other than coagulase-negative staphylococci that are most commonly
isolated from patients with nosocomial bloodstream infections (BSIs) and the associated crude mortality rates for patients in
intensive care units (ICU) and non-ICU wards
BSIs per 1000 patient-days Crude mortality (%)
April 8–March 9 April 9–March 10 April 10–March 11 April 11–March 12 Total ICU Non-ICU ward
Staphylococcus aureus 0.16 0.19 0.17 0.17 23.9 40.1 23.4
Enterococcus spp. 0.09 0.10 0.12 0.12 29.5 44.9 24.4
E. coli 0.13 0.15 0.16 0.17 14.1 30.0 12.2
Klebsiella spp. 0.09 0.11 0.13 0.11 19.6 47.1 16.4
Pseudomonas aeruginosa 0.07 0.06 0.07 0.06 20.3 46.0 12.7
Candida spp. 0.04 0.05 0.07 0.08 39.3 51.0 33.9
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rate was observed for pneumonia/empyema (44.1%), whereas
the lowest was associated with urinary tract infection (7.8%).
Discussion
Due to the increasing frequencies of antimicrobial resistance,
surveillance programmes for BSIs have become important for
deﬁning the species distribution and resistance patterns of
pathogens. This was the ﬁrst study in Japan to perform
clinically oriented surveillance by collecting data on deﬁned
infections rather than evaluating culture results alone. More-
over, this surveillance encompassed the entire hospitalized
population at the sentinel university hospitals rather than just
patients in ICUs.
One previous study demonstrated that the acquisition of
two sets of blood samples instead of just one led to better
performance when attempting to diagnose sepsis, thus
reﬂecting the quality of clinical practice for infection control
[12]. In this study, we calculated the percentage of multiple
blood culture sets taken. According to the study results, the
average rate of multiple blood culture sets has increased in
recent years but is still estimated to be much lower than the
rate reported for the United States [13,14]. Unfortunately,
there are few reports from other developed countries that
have evaluated the current blood culture practices related to
infectious diseases; therefore, we cannot compare our data
with those from other countries. However, the number of
blood culture sets taken per bed and per patient-day increased
in our cohorts during the study period; thus, infectious disease
practices have probably improved in the participating univer-
sity hospitals, all of which are tertiary-care hospitals and
employ a few full-time infectious diseases practitioners.
Conversely, we did not evaluate information from the
community hospitals or primary care hospitals, which usually
do not employ infectious diseases practitioners. To better
understand and evaluate the current infectious diseases
practices in Japan, a larger study that includes community
hospitals and is stratiﬁed according to the type of hospital
should be conducted. In the current study, the number of
blood culture sets taken and the rates of multiple blood
culture sets differed among the participating universities. Thus,
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FIG. 2. Rates of antimicrobial resistance over
time for gram-positive isolates (methicillin-
resistant Staphylococcus aureus (MRSA) and
ampicillin resistant Enterococcus spp.,), gram-
negative isolates (ampicillin-resistant Escherichia
coli, extended spectrum beta lactamase (ESBL)-
producing E. coli and Klebsiella spp., and Pseudo-
monas aeruginosa (ceftazidime resistant, metal-
lo-beta-lactamase producing isolates and
multidrug resistant isolates)). ESBL-producing
E. coli and Klebsiella spp. increased annually
whereas MRSA decreased from 2009 to 2011.
TABLE 2. Clinical characteristics of 2941 patients with nos-
ocomial BSIs
Patient demographics N = 2941 %
Age (years, average) 61.3
Paediatric 133 4.5
Adult 2806 95.4
Male 1769 60.1
ICU setting 366 12.4
Underlying conditions
Solid tumour 1166 39.6
Haematological malignancy 348 11.8
Diabetes mellitus 435 14.8
Liver dysfunction 182 6.2
Chronic kidney disease 149 5.1
Neutropenia 396 13.5
Collagen disease 100 3.4
Potential risk factors
Renal replacement therapy 309 10.5
Intravenous catheter 1268 43.1
Surgery within the previous month 665 22.6
Transplantation (bone marrow
transplantation) within the previous 6 months
82 2.8
Transplantation (solid organ) within
the previous 6 months
210 7.1
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further efforts are needed to encourage both infectious
diseases practitioners and attending physicians to collect
additional blood cultures for the accurate and appropriate
diagnosis of nosocomial BSIs. Ultimately, the results of such
efforts should enable us to gather feedback on the results of
the current study.
The rate of methicillin resistance that we identiﬁed among
S. aureus BSIs was higher than that identiﬁed in the Nether-
lands and Nordic countries but was comparable to the rates of
resistance reported in the United States and England [3,15–
17]. In England, the incidence of MRSA bacteraemia has
decreased through mandatory surveillance programmes in the
past 10 years [18]. Interestingly, the rate of methicillin
resistance reported in this study also decreased from 2009
to 2011. As this study period was not sufﬁcient to discuss the
trends, continuous monitoring of these resistance rates is
needed. In the current study, the rates of ESBL-producing
isolates of E. coli and Klebsiella spp. and multidrug-resistant
P. aeruginosa were much lower than those reported for the
United States [3,19]; however, the rates of ESBL-producing
isolates increased during the study period. According to
previous reports, ESBL-producing E. coli and Klebsiella spp.
with quinolone resistance are increasing worldwide, and the
relationship between this increase in ESBL-producing isolates
and quinolones consumption has been discussed elsewhere
[20,21]. In Japan, the increase in ESBL-producing E. coli with
quinolone resistance has been reported, which suggests that
BSIs due to ESBL-producing isolates may have also increased
accordingly [22]. In the current study, the rates of multidrug-
resistant isolates differed among some university hospitals;
multidrug-resistant isolates increased signiﬁcantly (data not
shown). Thus, continuous monitoring (ideally with interven-
tion) is needed to identify the optimal infection control
procedures and the optimal empirical therapy for sepsis in
each university hospital. Furthermore, increased monitoring is
especially warranted at those institutions with higher rates of
multidrug-resistant isolates, such as MRSA and ESBL-producing
isolates.
The case fatality rate observed in our study was consistent
with the results of previous investigations in the United States
and Israel but was signiﬁcantly lower than the rate reported in
a study from Brazil [3,5,6,10]. In general, the case fatality rates
of bloodstream infection were higher in patients infected with
multidrug-resistant isolates. The resistance rates of the
causative agents in our cohort were much lower than those
found in previous studies, which may have resulted in better
TABLE 3. Clinical characteristics and crude mortality rate by causative agent of BSIs.
Staphylococcus
aureus (N = 798)
Enterococcus
spp. (N = 424)
Escherichia
coli (N = 595)
Klebsiella
spp. (N = 501)
Pseudomonas
aeruginosa (N = 325)
Candida
spp. (N = 298)
Age, years 60.9 (range 0–92) 60.9 (range 0–92) 64.4 (range 2–84) 61.2 (range 2–87) 59.4 (range 5–88) 61.3 (range 0–89)
Male 450 (56.4%) 288 (67.9%) 352 (59.2%) 295 (58.9%) 205 (63.1%) 179 (60.1%)
Onset in the ICU 100 (12.5%) 71 (16.7%) 30 (5.0%) 50 (10.0%) 49 (15.1%) 66 (22.1%)
Multidrug-resistant
(MDR) isolates
393a (49.2%) 62b (10.4%) 38b (7.6%) 5c (1.5%)
Crude mortality rate of
MDR isolates
29.0%
114/393
21.0%
13/62
5.8%
2/38
60.0%
3/5
aMethicillin-resistant isolates.
bExtended-spectrum beta-lactamase-producing isolates.
cMultidrug-resistant isolates.
TABLE 4. Crude mortality rate by source and causative agent of BSIs
Staphylococcus
aureus
Enterococcus
spp.
Escherichia
coli
Klebsiella
spp.
Pseudomonas
aeruginosa
Candida
spp. Total
Catheter-related bloodstream infection 21.6% 34.1% 0.0% 18.6% 16.7% 36.2% 26.2%
73/338 15/44 0/15 8/43 3/18 75/207 174/665
Urinary tract infection 24.0% 12.0% 3.8% 6.5% 9.8% (–) 7.8%
12/50 3/25 9/234 5/77 5/51 (–) 34/437
Pneumonia/empyema 51.9% 45.5% (–) 42.5% 32.7% (–) 44.1%
41/79 5/11 (–) 17/40 16/49 (–) 79/179
Surgical site infection 25.0% 21.1% 11.5% 13.6% 11.5% (–) 19.0%
18/72 8/38 3/26 3/22 3/26 (–) 35/184
Skin and soft tissue infection 13.3% (–) (–) (–) 8.3% (–) 11.9%
4/30 (–) (–) (–) 1/12 (–) 5/42
Intra-abdominal infection 43.2% 40.4% 17.4% 18.2% 36.4% (–) 26.2%
16/37 36/89 23/132 25/137 12/33 (–) 112/428
Febrile neutropenia 32.0% 40.4% 16.4% 12.3% 22.0% (–) 22.7%
8/25 21/52 12/73 8/65 9/41 (–) 58/256
Focus unknown 28.2% 35.6% 32.3% 28.3% 32.1% 46.6% 32.4%
46/163 36/101 32/99 32/113 27/84 27/58 200/618
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prognosis for the patients included in this study [23–25].
Additionally, the composition of the study population may have
an impact on the overall results. For instance, more patients
with malignancy (51.4% vs. 24% in the Brazilian cohort and 17%
in the American cohort) are present in our cohort. The impact
of underlying diseases and indwelling devices on the outcome
of nosocomial infections was not clearly determined in this
study. However, high mortality rates were still observed
among BSI cases, although infectious disease practices clearly
improved over time.
In our multicentre study, we determined the current
epidemiological trends for nosocomial BSIs in Japanese
university hospitals and found that further efforts are needed
to improve the quality of infectious disease practices and
determine an optimal strategy for infection control.
Limitations of the Study
This study included only university hospitals; therefore, the
results may not be generalizable, and further studies are needed
to evaluate hospitals other than university hospitals. Second, no
severity-of-illness scores (e.g. NNIS or Pitt bacteraemia scores)
were employed, but these scores would have been most
important if the purpose of our study had been the determi-
nation and comparison of mortality rates, which was only a
minor objective of our study. Third, we collected data on only
six pathogens. In the future, we plan to evaluate the surveillance
of nosocomial BSIs caused by all species to determine the actual
burden of nosocomial BSIs in Japan.
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